Cannabis and Endometriosis: Why Women Are Turning to THC for Pain

Gender / Demographics

7-10 Year Delay

Endometriosis affects 190 million women with a 7-10 year diagnostic delay, and surveys consistently show patients rate cannabis among the most effective self-management strategies for pelvic pain.

Armour et al. (2019)

Armour et al. (2019)

View as image

Endometriosis is a condition in which tissue similar to the uterine lining grows outside the uterus, most commonly on the ovaries, fallopian tubes, pelvic peritoneum, and bowel. This displaced tissue responds to hormonal cycles, growing and shedding each month, but unlike normal endometrial tissue, it has no way to exit the body. The result is chronic inflammation, adhesions, and pain that can be severe and debilitating.

The numbers are staggering. Endometriosis affects an estimated 190 million women worldwide, approximately 10 percent of women of reproductive age. The average diagnostic delay is 7 to 10 years from symptom onset, partly because pelvic pain in women has historically been normalized and dismissed. Even after diagnosis, treatment options are limited. Hormonal therapies suppress the disease but do not cure it and come with their own side effects. Surgery can remove lesions but recurrence rates are high. Pain medications provide symptomatic relief but often inadequately.

Against this backdrop, it is not surprising that endometriosis patients are among the fastest-growing groups of medical cannabis users. They are dealing with a painful, chronic condition for which conventional medicine has incomplete answers. Cannabis represents another option, and many patients are finding it helpful. But the evidence base is early, and understanding what we know versus what we are still learning is important.

The Endocannabinoid System in Reproductive Tissue

Gender / Demographics

Cannabis & Endometriosis: The ECS Connection

CB1/CB2 in Reproductive Tissue

Data: Receptors expressed in endometrium, ovaries, fallopian tubes

Implication: Cannabinoids have biological access to disease site

Altered ECS in Lesions

Data: Endometriotic tissue shows different CB receptor expression + reduced FAAH

Implication: ECS is involved in disease process, not just bystander

Patient Surveys (Armour 2019)

Data: High satisfaction for pain reduction and quality of life

Implication: Patients finding relief, but no RCTs to confirm

Fertility Concern

Data: ECS plays role in ovulation and implantation; elevated anandamide linked to implantation failure

Implication: Caution needed if actively trying to conceive

Delivery Methods

Data: Suppositories and topicals growing in popularity

Implication: Zero clinical evidence for these specific formats

Armour et al. 2019 • Not medical adviceCannabis and Endometriosis

The endocannabinoid system has a significant presence in the female reproductive tract. CB1 and CB2 receptors are expressed in the endometrium, myometrium, ovaries, fallopian tubes, and vagina. Endocannabinoid levels fluctuate across the menstrual cycle, with anandamide levels peaking around ovulation and dropping during the luteal phase.

This is not a peripheral finding. The endocannabinoid system appears to play regulatory roles in endometrial function, implantation, and reproductive immunology. Disruptions in endocannabinoid signaling have been associated with conditions including infertility, miscarriage, and endometriosis.

In endometriotic tissue specifically, research has documented altered expression of cannabinoid receptors. A study by Sanchez and colleagues found that endometriotic lesions express both CB1 and CB2 receptors, and that the expression pattern differs from normal endometrium. Bilgic and colleagues found reduced FAAH expression in endometriotic tissue, suggesting altered endocannabinoid metabolism at the site of disease.

These findings suggest that the endocannabinoid system is not merely a bystander in endometriosis. It is involved in the disease process. Whether modulating this system with exogenous cannabinoids can improve outcomes is the question driving current research.

In preclinical studies, the results are encouraging. CB1 agonists have been shown to reduce the proliferation of endometriotic cells in culture. CB2 activation reduces the inflammatory milieu around endometriotic lesions in animal models. Endocannabinoid-degrading enzyme inhibitors (which increase local endocannabinoid levels) reduced endometriotic lesion size in rodent models.

Patient Survey Data

The clinical trial evidence for cannabis and endometriosis is limited, but patient survey data provides valuable insight into real-world use patterns and outcomes.

The Reinert 2021 study, published in the Journal of Minimally Invasive Gynecology, surveyed endometriosis patients about their cannabis use. The study found that a significant proportion of respondents used cannabis for symptom management and that the majority reported effectiveness for pain, sleep, and nausea. Self-reported pain scores improved, and many patients reported reducing their use of other pain medications.

An Australian survey by Armour and colleagues (2019), published in PLOS ONE, found that among women with endometriosis who used cannabis, the vast majority reported it as effective for pain management. Cannabis was rated as one of the most effective self-management strategies, alongside heat, dietary changes, and exercise.

A New Zealand survey by Sinclair and colleagues found similar patterns: endometriosis patients using cannabis reported improvements in pain, sleep, and nausea, with many reducing their use of conventional pain medications.

The consistency across countries and study designs strengthens the signal. Endometriosis patients who use cannabis report meaningful benefit. But these are surveys, not controlled trials. The placebo response in pain conditions is substantial, selection bias is inherent, and the products used are unstandardized.

Mechanism for Pain Relief

Endometriosis pain is complex, involving nociceptive, inflammatory, and neuropathic components. The condition produces pain through multiple pathways: direct irritation of pelvic structures by endometriotic lesions, inflammation-mediated sensitization of pelvic nerves, formation of adhesions that cause mechanical pain, and central sensitization that amplifies pain processing in the spinal cord and brain.

Cannabinoids address several of these pathways simultaneously.

Nociceptive pain: THC activates CB1 receptors on sensory nerve endings in pelvic tissue, reducing the transmission of pain signals. CBD modulates TRPV1 channels, which are involved in pain sensing and are upregulated in conditions of chronic inflammation.

Inflammatory pain: Both THC and CBD reduce pro-inflammatory cytokine production. CB2 activation on immune cells in the peritoneal cavity could reduce the inflammatory environment around endometriotic lesions. CBD additionally activates PPARgamma, a nuclear receptor involved in regulating inflammatory gene expression.

Neuropathic pain: Endometriosis can cause neuropathic pain through nerve infiltration by endometriotic lesions and chronic inflammation-induced nerve damage. Neuropathic pain is the pain category with the strongest evidence for cannabinoid treatment, making this component theoretically responsive.

Central sensitization: Chronic pelvic pain from endometriosis leads to central sensitization, where the spinal cord and brain become hyper-responsive to pain signals. CB1 receptors in the dorsal horn of the spinal cord and in supraspinal pain regions modulate central sensitization, potentially reducing amplified pain processing.

THC vs. CBD for Endometriosis Pain

The relative roles of THC and CBD for endometriosis pain have not been directly compared in clinical studies. Based on general cannabinoid pharmacology and patient reports, both likely contribute through different mechanisms.

THC provides stronger acute analgesic effects through direct CB1 activation. For patients whose primary need is pain relief during severe episodes (menstruation, flares, post-surgical recovery), THC-containing products are likely more effective. The trade-off is psychoactive effects, which some patients find therapeutic (relaxation, mood improvement) and others find undesirable.

CBD provides anti-inflammatory effects and modulates pain without intoxication. For daily use aimed at reducing baseline inflammation and maintaining function, CBD may be more practical. CBD also has anxiolytic properties that may help the anxiety and emotional distress that commonly accompany chronic endometriosis pain.

Many patients find that a combination approach works best: CBD-dominant products for daily use and THC-containing products for pain flares and nighttime use. This is consistent with general cannabinoid therapy principles but has not been validated for endometriosis specifically.

Delivery Methods: Suppositories and Beyond

Cannabis suppositories, both vaginal and rectal, have gained popularity among endometriosis patients. The appeal is intuitive: delivering cannabinoids directly to the site of pelvic pathology. Companies in legal cannabis markets now offer suppository products specifically marketed for pelvic pain.

The pharmacological basis for this approach is plausible but unproven. Vaginal and rectal mucosa are absorptive surfaces that could deliver cannabinoids to pelvic tissue more directly than oral or inhaled routes. The pelvic venous plexus drains to the inferior vena cava, potentially allowing cannabinoids absorbed from suppositories to reach pelvic tissue at higher local concentrations than systemic administration would achieve.

However, no clinical trial has tested cannabis suppositories for endometriosis or any gynecological pain condition. The bioavailability of cannabinoids from suppositories is not well-characterized. Patient reports are positive, but the placebo effect of a novel, intuitively appealing delivery method cannot be discounted.

Other delivery methods used by endometriosis patients include oral oils and capsules (consistent dosing, longer duration, suitable for daily use), inhaled cannabis (rapid onset for acute pain episodes), topical products applied to the lower abdomen (limited evidence for skin penetration to pelvic structures), and sublingual tinctures (faster onset than oral, more convenient than inhalation).

Interactions with Hormonal Treatments

Most endometriosis patients take hormonal medications, including combined oral contraceptives, progestins, GnRH agonists, or aromatase inhibitors. Understanding potential interactions with cannabis is important.

The interaction between cannabinoids and hormonal treatments has not been extensively studied. What we know is that both THC and CBD are metabolized by hepatic cytochrome P450 enzymes, the same enzyme system that metabolizes most hormonal medications. CBD inhibits CYP3A4, which is involved in the metabolism of ethinyl estradiol and many progestins. This could theoretically alter the effectiveness of hormonal contraceptives, though the clinical significance at typical cannabis doses is uncertain.

Endometriosis patients using GnRH agonists (leuprolide, goserelin) experience a medically induced menopause with side effects including hot flashes, mood disturbance, and bone density loss. Cannabis may help manage some of these side effects, particularly mood disturbance and sleep disruption, though this has not been formally studied.

Patients should inform their gynecologist about cannabis use so that hormonal treatment can be monitored and adjusted if needed.

Fertility Considerations

Many endometriosis patients are concerned about fertility, as the condition is a leading cause of infertility. The impact of cannabis on fertility is an important consideration for this population.

The endocannabinoid system plays documented roles in ovulation, implantation, and early pregnancy. Elevated anandamide levels are associated with implantation failure in human studies. THC can disrupt the hypothalamic-pituitary-gonadal axis and may affect ovulation.

For endometriosis patients who are actively trying to conceive, cannabis use should be approached with caution and ideally discontinued during conception attempts and pregnancy. This recommendation is based on general reproductive safety data rather than endometriosis-specific studies, but the theoretical risks are significant enough to warrant caution.

For patients who are not currently trying to conceive, the fertility implications are less immediate but should be part of the conversation with their healthcare team.

What Gynecologists Say

Most gynecologists who address cannabis and endometriosis publicly acknowledge the reality that their patients are using it and that patient satisfaction is high. Their concerns mirror those of other specialists: insufficient clinical trial evidence, product variability, potential hormonal interactions, and the risk that patients may delay or abandon proven treatments.

The American College of Obstetricians and Gynecologists (ACOG) has not issued specific guidance on cannabis for endometriosis. Their general position on cannabis in women's health is cautious, emphasizing the need for more research and the risks during pregnancy and breastfeeding.

Individual gynecologists range from supportive to skeptical. Those who support its use typically frame cannabis as a reasonable option for patients with refractory pain who have tried conventional treatments. Those who are more cautious emphasize the evidence gaps and the importance of maintaining hormonal and surgical treatment plans.

Practical Framework

For endometriosis patients who have discussed cannabis with their gynecologist and want to explore it for symptom management, the following framework provides a starting point.

Begin with CBD-only products for two to four weeks. Start at 10 to 25 mg twice daily. This establishes a baseline and provides anti-inflammatory and anxiolytic effects without psychoactive concerns.

If additional pain relief is needed, add low-dose THC. Start with 2.5 mg THC in the evening and increase gradually based on response. Many patients find their effective dose in the 2.5 to 10 mg THC range.

Time cannabis use to your menstrual cycle. Pain is typically worst during menstruation. Increasing the dose or adding THC during the menstrual phase and reducing during less symptomatic phases is a practical approach that many patients adopt.

Consider delivery method based on your needs. Oral products for consistent daily management, inhaled for acute pain breakthrough, and suppositories if you want to try targeted pelvic delivery, understanding that the evidence for this route is limited.

Do not abandon hormonal treatment or surgical recommendations. Cannabis addresses symptoms but has not been shown to modify the disease. Endometriosis can progress and cause irreversible damage, including to fertility.

Track your response systematically. Pain scores, medication use, functional ability, and menstrual cycle phase should all be documented to determine whether cannabis is genuinely helping.

The Bottom Line

Endometriosis patients have legitimate reasons to seek alternatives to conventional pain management, and cannabis is the alternative they are finding most accessible. The biological rationale is strong, with the endocannabinoid system deeply embedded in reproductive tissue and pain processing. Patient survey data is consistently positive. The evidence gap is in controlled clinical trials, which are needed to establish efficacy, optimal dosing, and safety in this population.

Cannabis is not a cure for endometriosis. It does not remove lesions, prevent adhesions, or restore fertility. What it may offer is a more tolerable way to manage the chronic pain and associated symptoms that make endometriosis so debilitating. For patients who have not found adequate relief from conventional treatments, a careful trial under medical guidance is a reasonable step.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your treatment plan.

The Bottom Line

Evidence review of cannabis for endometriosis covering reproductive ECS, patient surveys, pain mechanisms, THC vs CBD, delivery methods, hormonal interactions, and fertility. Reproductive ECS: CB1/CB2 in endometrium, ovaries, fallopian tubes; anandamide peaks at ovulation; Sanchez — altered cannabinoid receptor expression in endometriotic lesions; Bilgic — reduced FAAH in endometriotic tissue; preclinical: CB1 agonists reduce endometriotic cell proliferation, CB2 activation reduces perilesional inflammation. Patient surveys: Reinert 2021 Journal of Minimally Invasive Gynecology — high satisfaction, pain reduction, reduced other medication use; Armour 2019 PLOS ONE (Australia) — cannabis rated among most effective self-management strategies; Sinclair (New Zealand) — improvements in pain, sleep, nausea. Pain mechanisms: nociceptive (CB1 on pelvic sensory nerves), inflammatory (CB2 on peritoneal immune cells, PPARgamma), neuropathic (nerve infiltration by lesions, strongest cannabinoid evidence category), central sensitization (CB1 in dorsal horn). Delivery: oral for daily management; inhaled for acute breakthrough; suppositories (vaginal/rectal) popular but no clinical trials, bioavailability uncharacterized. Hormonal interactions: CBD inhibits CYP3A4 → may affect ethinyl estradiol/progestin metabolism; cannabis may help GnRH agonist side effects (mood, sleep). Fertility: ECS roles in ovulation/implantation; elevated anandamide = implantation failure; caution/discontinuation during conception attempts.

Frequently Asked Questions

Does cannabis help endometriosis pain?

Patient surveys consistently report meaningful benefit. The Reinert 2021 study (Journal of Minimally Invasive Gynecology) found high satisfaction rates with pain reduction and improved quality of life. An Australian survey (Armour 2019, PLOS ONE) rated cannabis among the most effective self-management strategies. The biological rationale is strong — endometriosis pain involves nociceptive, inflammatory, neuropathic, and central sensitization components, and cannabinoids address multiple pathways simultaneously. However, controlled clinical trials specific to endometriosis are lacking.

Do cannabis suppositories work for pelvic pain?

The appeal is intuitive — delivering cannabinoids directly to pelvic tissue. The pharmacological basis is plausible (vaginal/rectal mucosa is absorptive, pelvic venous plexus could deliver cannabinoids locally at higher concentrations), and patient reports are positive. However, no clinical trial has tested cannabis suppositories for endometriosis or any gynecological pain condition. The bioavailability from suppositories is not well-characterized, and the placebo effect of a novel delivery method cannot be discounted.

Is CBD or THC better for endometriosis?

They likely contribute through different mechanisms. THC provides stronger acute analgesic effects through direct CB1 activation — more effective for severe pain episodes during menstruation or flares. CBD provides anti-inflammatory effects and modulates pain without intoxication, more practical for daily baseline management. Many patients find a combination works best: CBD-dominant products daily and THC-containing products for pain flares and nighttime. This approach is consistent with general cannabinoid therapy principles but has not been validated for endometriosis specifically.

Does cannabis affect fertility in endometriosis patients?

This is a significant concern. The endocannabinoid system plays documented roles in ovulation, implantation, and early pregnancy. Elevated anandamide levels are associated with implantation failure in human studies, and THC can disrupt the hypothalamic-pituitary-gonadal axis. For endometriosis patients actively trying to conceive, cannabis use should be approached with caution and ideally discontinued during conception attempts and pregnancy. For patients not currently trying to conceive, the implications are less immediate but should be discussed with their healthcare team.

Does cannabis interact with hormonal endometriosis treatments?

Potentially. CBD inhibits CYP3A4, which metabolizes ethinyl estradiol and many progestins — this could theoretically alter hormonal contraceptive effectiveness, though clinical significance at typical cannabis doses is uncertain. For patients on GnRH agonists (leuprolide, goserelin), cannabis may actually help manage medically induced menopause side effects like mood disturbance and sleep disruption, though this has not been formally studied. Inform your gynecologist about cannabis use so hormonal treatment can be monitored.

Can cannabis replace surgery or hormonal treatment for endometriosis?

No. Cannabis addresses symptoms but has not been shown to modify the disease. It does not remove lesions, prevent adhesions, or restore fertility. Endometriosis can progress and cause irreversible damage, including to fertility, if disease-modifying treatments are abandoned. Cannabis is best considered a potential adjunct for pain management in patients who have not found adequate relief from conventional treatments, used under medical guidance alongside — not instead of — hormonal and surgical recommendations.